Chinese Hepatolgy ›› 2024, Vol. 29 ›› Issue (5): 521-525.

• Liver Fibrosis & Cirrhosis • Previous Articles     Next Articles

The value of a combination of serum β-arrestin 2, HIF-1α and CA125 to predict hepatic fibrosis in chronic hepatitis B patients

WANG Lei1, CHEN Chen2, HUA Xi-mei3, HU Feng-fen4   

  1. 1. Department of Medical Laboratory, Suqian First People′s Hospital, Jiangsu 223800, China;
    2. General Surgery Hepatobiliary Department, Suqian First People′s Hospital, Jiangsu 223800, China;
    3. Laboratory of Shuyang County Center for Disease Control and Prevention, Jiangsu223600, China;
    4. Department of Medical Laboratory, Shuyang County Traditional Chinese Medicine Hospital, Jiangsu 223800, China
  • Received:2023-06-09 Online:2024-05-31 Published:2024-08-28
  • Contact: CHEN Chen,Email:cyogurtc@126.com

PDF (PC)

33

Abstract: Objective To investigate the value of serum β-inhibitory protein 2 (β-arrestin 2), hypoxia-inducing factor 1α (HIF-1α) and carbohydrate antigen 125 (CA125) in the prediction of hepatic fibrosis in chronic hepatitis B (CHB) patients. Methods One hundred and ten CHB patients admitted from May 2019 to May 2022 were selected as the study subjects, and were set as the observation group. Another 110 healthy people who were examined in the physical examination center at the same period of time were selected as the control group. The serum β-arrestin 2, HIF-1α, CA125 were compared between the two groups of people, and the above indicators in patients with different pathological stages of liver fibrosis were observed. Receiver operating characteristic curve (ROC) analysis was used to determine the value of the above indexes in predicting liver fibrosis stage 4 (S4) in CHB patients., Multiple logistic regression analysis was used to identify the risk factors of S4 CHB, Pearson correlation analysis was used to analyze the correlation between the above indexes and the pathological stage of cirrhosis. Results Compared with the control group, serum β-arrestin2, HIF-1α and CA125 levels in observation group were significantly increased (t=21.376, 21.548, 71.752, P<0.05). The serum β-arrestin2, HIF-1α and CA125 levels were increased gradually in CHB patients with S1, S2, S3 and S4 of hepatic fibrosis (F=140.309, 63.837, 82.963, P<0.05). It was proved by ROC analysis that serum β-arrestin2, HIF-1α and CA125 levels could be used to predict S4 of CHB, with the areas under the curve (AUC) of 0.984, 0.926 and 0.956, respectively. The combined diagnosis could obtain a higher AUC as 0.999 (P<0.05). Multivariate logistic regression analysis showed that β-arrestin2≥96.37 pg/mL (OR=2.011, 95%CI: 1.211~3.339), HIF-1α≥74.345 μg/L (OR=1.696, 95%CI: 1.026~2.804), CA125≥173.27 U/mL (OR=2.117, 95%CI: 1.974~3.987) were risk factors for S4. Serum β-arrestin2, HIF-1a, CA125 levels were positively correlated with hepatic fibrosis stages in CHB patients (r=0.458, 0.651, 0.531, all P<0.05). Conclusion Serum β-arrestin2, HIF-1α and CA125 levels can all be used to predict liver fibrosis stages in CHB patients. The higher the level of the aboval indexes, the more severe in the degree of liver fibrosis. The sensitivity of a combined application was higher than individual index. A combined diagnosis with multiple parameters may further improve the objectivity and accuracy of the diagnosis, and reduce the occurrence of missed diagnosis and misdiagnosis. It provides a reliable basis for clinical practice thus worthy of clinical promotion.

Key words: Serum beta-inhibitory protein 2, Hypoxia-inducing factor 1α, Carbohydrate antigen 125, Chronic hepatitis B, Hepatic fibrosis